Skip to Main Content

Author Details

Michael T Lewis
Baylor College of Medicine
1996
115
45
PMIDPaper TitleJournal TitlePublished Year
36880458RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.EMBO Mol Med2023
37578979Deconvolution of cancer cell states by the XDec-SM method.PLoS Comput Biol2023
36961012Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography2023
36880458RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.EMBO Mol Med2023
37071495Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Cancer Res2023
37578979Deconvolution of cancer cell states by the XDec-SM method.PLoS Comput Biol2023
37071495Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer.Cancer Res2023
36961012Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography2023
35017531MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.Nat Commun2022
36042336Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.Nature2022
35767427Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma.Anal Chem2022
35585241PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.Nature2022
35697909In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.J Mammary Gland Biol Neoplasia2022
36088362Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts.NPJ Breast Cancer2022
35881233Correction to: In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.J Mammary Gland Biol Neoplasia2022
36001024Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.Cancer Discov2022
35857626Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.Sci Transl Med2022
36619972Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.iScience2022
35175598Surgical Procedure for Implantation of Human Tumor Tissue into the Epithelium-Free Mammary Fat Pad of Immunocompromised Mice to Generate Patient-Derived Xenografts (PDX).Methods Mol Biol2022
35017531MAPK4 promotes triple negative breast cancer growth and reduces tumor sensitivity to PI3K blockade.Nat Commun2022
34996889Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.Nat Commun2022
35221336A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.Nat Cancer2022
35585241PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.Nature2022
35767427Internal Standard Triggered-Parallel Reaction Monitoring Mass Spectrometry Enables Multiplexed Quantification of Candidate Biomarkers in Plasma.Anal Chem2022
35697909In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.J Mammary Gland Biol Neoplasia2022
35857626Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.Sci Transl Med2022
36619972Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.iScience2022
36001024Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.Cancer Discov2022
36042336Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.Nature2022
36088362Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenografts.NPJ Breast Cancer2022
35881233Correction to: In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.J Mammary Gland Biol Neoplasia2022
35221336A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology.Nat Cancer2022
35175598Surgical Procedure for Implantation of Human Tumor Tissue into the Epithelium-Free Mammary Fat Pad of Immunocompromised Mice to Generate Patient-Derived Xenografts (PDX).Methods Mol Biol2022
34996889Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.Nat Commun2022
33299122VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk.Oncogene2021
33450205Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.Cell2021
33299122VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk.Oncogene2021
34711608Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.Cancer Res2021
34429404Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Nat Commun2021
35156101Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.Cancer Res Commun2021
35156101Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics.Cancer Res Commun2021
34429404Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.Nat Commun2021
34711608Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.Cancer Res2021
33450205Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.Cell2021
32321829Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.Proc Natl Acad Sci U S A2020
32321829Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.Proc Natl Acad Sci U S A2020
32478757Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer.J Vis Exp2020
32879897Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine.Tomography2020
32705545Hoxd10 Is Required Systemically for Secretory Activation in Lactation and Interacts Genetically with Hoxd9.J Mammary Gland Biol Neoplasia2020
32634121MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.JCI Insight2020
  • 1 - 50 of 230

Recommended Authors

Pirashaanthy Tharmapalan
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 2012
Number of shared co-authors 1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Daniel Schramek
University of Toronto
Career Start Year 2005
Number of shared co-authors 5
Mona Shehata
University of Cambridge
Career Start Year 2004
Number of shared co-authors 1
Donghui Cheng
University of California los angeles
Career Start Year 2003
Number of shared co-authors 0
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 2
Danh Tran-Thanh
Centre Hospitalier de l'Universite de Montreal
Career Start Year 2002
Number of shared co-authors 0
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 4
Matthew J Smalley
European Cancer Stem Cell Research Institute, Cardiff University
Career Start Year 1998
Number of shared co-authors 6
Jianjun Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 1998
Number of shared co-authors 4
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 2
Hal K Berman
Princess Margaret Cancer Centre, University Health Network
Career Start Year 1997
Number of shared co-authors 1
Marc Vooijs
Maastricht University Medical Centre+
Career Start Year 1997
Number of shared co-authors 2
Jun Yao
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 5
Hai Hu
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 3
Alexander D Borowsky
University of California Davis Health
Career Start Year 1995
Number of shared co-authors 5
Susan J Done
University Health Network
Career Start Year 1994
Number of shared co-authors 0
Sandra Orsulic
David Geffen School of Medicine, University of California at Los Angeles
Career Start Year 1992
Number of shared co-authors 4
Senthil K Muthuswamy
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1992
Number of shared co-authors 2
Kornelia Polyak
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School
Career Start Year 1991
Number of shared co-authors 11
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 7
Eldad Zacksenhaus
University of Toronto
Career Start Year 1988
Number of shared co-authors 1
Louis Gaboury
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Career Start Year 1986
Number of shared co-authors 0
Anthony E Oro
Stanford University
Career Start Year 1985
Number of shared co-authors 4
Alfredo A Molinolo
University of California
Career Start Year 1984
Number of shared co-authors 1
Sunil R Lakhani
University of Queensland
Career Start Year 1983
Number of shared co-authors 9
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Career Start Year 1982
Number of shared co-authors 13
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 1
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 17
Christopher C Benz
Buck Institute for Research on Aging
Career Start Year 1977
Number of shared co-authors 9

Collaborators

Lacey E Dobrolecki
Co-authored papers 39
Susan G Hilsenbeck
Co-authored papers 23
Chad J Creighton
Co-authored papers 13
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 12
Matthew J Ellis
Co-authored papers 11
Shunqiang Li
Co-authored papers 8
Alana L Welm
Huntsman Cancer Institute, University of Utah
Co-authored papers 8
Mothaffar F Rimawi
Co-authored papers 7
Charles Kent Osborne
Co-authored papers 7
Bryan E Welm
Co-authored papers 5
Matthew H Bailey
Department of Biology at Brigham Young University
Co-authored papers 4
Charles M Perou
Co-authored papers 4
Bing Zhang
Baylor College of Medicine
Co-authored papers 4
Anna Malovannaya
Co-authored papers 4
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 4
Adrian V Lee
Co-authored papers 4
Anna C Pavlick
Co-authored papers 4
Jonathan T Lei
Co-authored papers 4
Max S Wicha
Co-authored papers 3
James H Doroshow
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Beom-Jun Kim
Asan Medical Center, University of Ulsan College of Medicine
Co-authored papers 3
Donald C Allred
Co-authored papers 3
Alejandra Bruna
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 3
Yvonne A Evrard
Frederick National Laboratory for Cancer Research, Inc.
Co-authored papers 3
Purba Singh
Co-authored papers 3
Stephen T C Wong
Houston Methodist Research Institute
Co-authored papers 3
Varduhi Petrosyan
Co-authored papers 3
Meenakshi Anurag
Co-authored papers 3
Fabio Stossi
Co-authored papers 3
Xuxu Gou
Co-authored papers 3
Release 1.2